CAR T cell therapy: looking back and looking forward

Recent progress indicates a considerably improved mechanistic understanding of CAR T cell biology and delivers important insights into why some patients achieve durable remissions and others do not. In addition, although most success has been achieved in the context of CAR T cells targeted to B cell tumor antigens, namely CD19 and BCMA, we are seeing promising clinical trial outcomes for solid tumor malignancies.

Automated summary

Recent progress in CAR T cell biology has improved our understanding of the mechanisms behind durable remissions in some patients. Additionally, promising clinical trial outcomes are being observed in the treatment of solid tumor malignancies using CAR T cells targeting B cell tumor antigens.